<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949530</url>
  </required_header>
  <id_info>
    <org_study_id>Indalo (IDL)-2965-IPF-001</org_study_id>
    <secondary_id>2019-000173-23</secondary_id>
    <nct_id>NCT03949530</nct_id>
  </id_info>
  <brief_title>A Study of Safety &amp; Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis</brief_title>
  <official_title>IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indalo Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indalo Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and tolerability of the drug candidate&#xD;
      IDL-2965 and to see how it is absorbed, processed, and removed by the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IDL-2965 is an oral integrin antagonist antifibrotic being studied as a potential treatment&#xD;
      for IPF and Nonalcoholic Steatohepatitis (NASH). This double-blind, randomized,&#xD;
      placebo-controlled, single and multiple oral dose study will be conducted in 3 parts. Part A&#xD;
      will comprise a single-dose, sequential-group design in healthy subjects, incorporating a&#xD;
      food-effect evaluation. Part B will consist of a multiple-dose, sequential-group design in&#xD;
      healthy subjects. Part C will be a multiple-dose, sequential-group design in subjects with&#xD;
      IPF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to development challenges associated with the SARS-CoV-2 pandemic and emerging nonclinical&#xD;
    data&#xD;
  </why_stopped>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Actual">March 29, 2020</completion_date>
  <primary_completion_date type="Actual">March 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent Adverse Events (AEs), AEs leading to discontinuation from Investigational Medicinal Product (IMP) or the study, serious adverse events (SAEs), and deaths.</measure>
    <time_frame>Single Ascending Dose (SAD): up to 7 Days/ Multiple Ascending Dose (MAD): up to 21 Days/ IPF MAD: up to 40 Days</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>SAD: up to 7 Days / MAD: up to 21 Days / IPF MAD: up to 40 Days</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to 24 hours</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Pharmacodynamic (PD)</measure>
    <time_frame>SAD: up to 7 Days / MAD: up to 21 Days / IPF MAD: up to 28 Days</time_frame>
    <description>Change from baseline in phosphorylated small mothers against decapentaplegic (pSMAD) from bronchoalveolar lavage fluid cells</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>IDL-2965 Oral Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDL-2965 oral capsule, single and multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule, single and multiple doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDL-2965 Oral Capsule</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>IDL-2965 Oral Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
        • Male and female subjects aged between 18 and 60 years, with a body mass index between&#xD;
        18.0 and 32.0 kg/m2.&#xD;
&#xD;
        IPF subjects:&#xD;
&#xD;
          -  Male and female subjects over 40 years of age.&#xD;
&#xD;
          -  Diagnosis of idiopathic pulmonary fibrosis&#xD;
&#xD;
          -  Idiopathic pulmonary fibrosis has been stable for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy subjects and IPF subjects:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any disease/disorder, other than IPF.&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Use or intend to use any medications, tobacco or nicotine containing products or&#xD;
             electronic cigarettes.&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs&#xD;
&#xD;
        IPF subjects:&#xD;
&#xD;
        • Pulmonary function tests and other diagnostic procedures inconsistent with diagnosis of&#xD;
        idiopathic pulmonary fibrosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MRCS FFPM</last_name>
    <role>Study Director</role>
    <affiliation>Indalo Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance CRU</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

